Perceptive Advisors

Type

Venture Capital

Status

Active

Location

New York, United States

Total investments

276

Average round size

96M

Portfolio companies

203

Rounds per year

11.04

Lead investments

59

Follow on index

0.26

Exits

109

Stages of investment
Private EquityEarly Stage VentureLate Stage Venture
Areas of investment
BiotechnologyHealth CareHealth DiagnosticsGeneticsMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsBiopharma

Summary

The venture was found in North America in United States. The main department of described VC is located in the New York.

We also calculated 3 valuable employees in our database.

The fund is constantly included in 2-6 investment rounds annually. The top activity for fund was in 2019. This Perceptive Advisors works on 28 percentage points more the average amount of lead investments comparing to the other organizations. The real fund results show that this VC is 13 percentage points more often commits exit comparing to other companies. The typical startup value when the investment from Perceptive Advisors is 100-500 millions dollars. The common things for fund are deals in the range of 50 - 100 millions dollars. The increased amount of exits for fund were in 2018.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Allogene Therapeutics, BridgeBio, Alector. The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. Among the most successful fund investment fields, there are Genetics, Biopharma.

The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Perceptive Advisors, startups are often financed by Third Rock Ventures, F-Prime Capital, Morgenthaler Ventures. The meaningful sponsors for the fund in investment in the same round are ArrowMark Partners, RTW Investments LLC, Viking Global Investors. In the next rounds fund is usually obtained by OrbiMed, Pontifax, Warburg Pincus.

Show more

Investor highlights

Industry focus
Biotech/Life SciencesMedtechHealthcare
Stage focus
Seed
Geo focus
Generalist
Check size
15M — 200M

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
276
Lead investments
59
Exits
109
Rounds per year
11.04
Follow on index
0.26
Investments by industry
  • Biotechnology (221)
  • Health Care (158)
  • Medical (100)
  • Therapeutics (90)
  • Pharmaceutical (72)
  • Show 57 more
Investments by region
  • United States (235)
  • United Kingdom (12)
  • China (3)
  • Germany (6)
  • Canada (7)
  • Show 7 more
Peak activity year
2021
Number of Unicorns
5
Number of Decacorns
5
Number of Minotaurs
14

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
11
Avg. valuation at time of investment
75M
Group Appearance index
0.87
Avg. company exit year
10
Avg. multiplicator
0.99
Strategy success index
1.00

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Capstan Therapeutics 20 Mar 2024 Biotechnology, Health Care, Therapeutics Early Stage Venture 175M United States, California, San Diego
Talkiatry 18 Jun 2024 Fitness, Health Care, Medical Late Stage Venture 130M United States, New York, New York

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.